Clinical Trial

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 24, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).
Trial Details
NCT Number NCT06009029
Lead Sponsor Peking University Third Hospital
Conditions Locally Advanced Pancreatic Cancer
Enrollment 96 participants
Start Date 2023-08
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2023-08-24